CGON experienced severe financial deterioration with cash reserves plummeting 87% to $32.5M while losses nearly doubled to $161M, creating potential liquidity concerns for this single-asset biotech company.
The dramatic cash burn acceleration combined with the 87% decline in cash reserves raises immediate questions about the company's ability to fund operations and complete clinical development of cretostimogene. With only $32.5M remaining and operating cash flow losses of $132M annually, CGON likely faces near-term financing needs that could result in significant dilution or strategic alternatives.
CGON's financial position deteriorated sharply across all metrics, with cash declining from $257M to just $32.5M while net losses expanded from $88M to $161M driven by 42% higher R&D spending. Operating cash outflows worsened 68% to $132M, while total liabilities increased 82% to $39M, indicating accelerated spending likely related to advancing their sole product candidate through clinical trials. The combination of rapidly depleting cash reserves and substantially higher burn rate signals an urgent need for additional financing to continue operations.
Cash declined 87.4% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Net income declined 82.9% — review whether driven by operations, interest costs, or non-recurring items.
Liabilities grew 82% — significant increase in debt or obligations, assess impact on financial flexibility.
Operating cash flow fell 68.1% — earnings quality concerns; investigate working capital changes and non-cash items.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Current liabilities surged 44.3% — significant near-term obligations; verify ability to meet short-term debt.
Capex reduced 42.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
R&D investment increased 42.1% — signals commitment to future product development, though near-term margin impact.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →